Opinion|Videos|March 6, 2025
The Safety Profile of RAD-ENZ
Panelists discuss how the combination of radium-223 and enzalutamide (RAD-ENZ) demonstrated a manageable safety profile in PEACE-3, with bone health monitoring and prophylactic bone-targeted therapy being crucial considerations, particularly given the potential impact on future treatment options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you discuss the safety profile of the combination of RAD-ENZ?
- Keeping the safety profile of RAD-ENZ in mind, do you have any concerns about implementing the PEACE 3 protocol and introducing radium treatment as you are thinking about the possible need for future therapies?
Advertisement
Related to this article
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
Experts review evidence on testosterone and prostate cancer
3
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
4
Carotuximab plus apalutamide shows interim PFS benefit in mCRPC
5